The patterns of association between PGRS and biomarker groups (that differs from the APOE association with biomarker groups) highlights the need to better understand the genetic architecture of the neuropathological features of AD, and characterize how genetic factors differentially drive the neuropathological and clinical progression in AD. This evidence concerns the gene APOE and Alzheimer disease.